Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 19/20 | 0.63 |
| ▸ | CXCR1 | P25024 | 9/20 | 0.60 |
| ▸ | CCR7 | P32248 | 1/20 | 0.60 |
| ▸ | CCR6 | P51684 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20452589 | 1.00 | CXCR2 (0.63) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL9979980 | 0.90 | CXCR2 (0.52) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL9980086 | 0.88 | CXCR2 (0.74) | CXCR2CXCR1 | |
| SCHEMBL9979984 | 0.88 | CXCR2 (0.74) | CXCR2CXCR1 | |
| SCHEMBL12310920 | 0.86 | CXCR2 (0.75) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12263082 | 0.85 | CXCR2 (0.73) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12263119 | 0.85 | CXCR2 (0.73) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12263053 | 0.81 | CXCR2 (0.65) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12087081 | 0.80 | CXCR2 (0.76) | CXCR2CXCR1CCR7CCR6 | |
| SCHEMBL12087027 | 0.80 | CXCR2 (0.76) | CXCR2CXCR1CCR7CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | ARISTEA THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | ARDEA BIOSCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | ARDEA BIOSCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| WO-2019055509-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20180235964-A1 | CXCR-2 INHIBITORS FOR TREATING CRYSTAL ARTHROPATHY DISORDERS | ARDEA BIOSCIENCES, INC. | 2018-08-23 | — | — | US | disclosed |
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | ARDEA BIOSCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| WO-2017156270-A1 | CXCR-2 INHIBITORS FOR TREATING CRYSTAL ARTHROPATHY DISORDERS | ARDEA BIOSCIENCES, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| EP-2651891-B1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-8648118-B2 | Bicyclic ring system substituted amide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-8648118-B2 | Bicyclic ring system substituted amide functionalised phenols as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012080456-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180235964-A1 | CXCR-2 INHIBITORS FOR TREATING CRYSTAL ARTHROPATHY DISORDERS | CXCR1, CXCR2, CXCR6 | CXCR2 2/4885CXCR1 1/4885CCR7 24/4885 |
| US-20180221312-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | CXCR1, CXCR2, CXCR6 | CXCR2 2/4885CXCR1 1/4885CCR7 15/4885 |
| US-10772886-B2 | CXCR-2 inhibitors for treating crystal arthropathy disorders | CXCR1, CXCR2, CXCR6 | CXCR2 2/4885CXCR1 1/4885CCR7 26/4885 |
| US-20230210792-A1 | USE OF A COMBINATION OF COLCHICINE AND A CXCR-2 INHIBITORS FOR THE TREATMENT OR PREVENTION OF FAMILIAL MEDITERRANEAN FEVER (FMF) AND FLARE-UPS THEREOF | CXCR1, CXCR2, FPR2 | CXCR2 2/4885CXCR1 1/4885CCR7 23/4885 |
| US-20120329773-A1 | BICYCLIC RING SYSTEM SUBSTITUTED AMIDE FUNCTIONALISED PHENOLS AS MEDICAMENTS | CXCR2, CCR2, CCR1 | CXCR2 1/4885CXCR1 5/4885CCR7 26/4885 |
| US-20200281878-A1 | CXCR-2 INHIBITORS FOR TREATING DISORDERS | CXCR1, CXCR2, CXCR6 | CXCR2 2/4885CXCR1 1/4885CCR7 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.